Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.

You may also be interested in...



Remote Monitoring A Potential Strategy To Recruit Older Adults Into Oncology Trials

Final FDA guidance also suggests sponsors recruit representative populations and limit exclusions.

New Acting US FDA Commissioner Shares Agency's Clinical Trial Reform Message

Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs.

Large Simple Trials Need FDA Boost, IoM Report Says

“Clear specific guidance” from the agency would help close the perception gap between what types of data industry thinks FDA wants and what the agency actually expects, according to a summary of a 2012 Institute of Medicine workshop.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS005655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel